Celcuity to Participate in Upcoming Craig-Hallum and Jefferies Investor Conferences

Rhea-AI Summary

MINNEAPOLIS, MN / ACCESSWIRE / May 26, 2022 / Celcuity (NASDAQ:CELC) announced that CEO Brian Sullivan will participate in two investor conferences: the 19th Annual Craig-Hallum Institutional Investor Conference on June 1, 2022 (virtual), and a fireside chat at the Jefferies Healthcare Conference in New York on June 9, 2022, at 2:30 p.m. ET. A live webcast will be available for the Jefferies event. Celcuity focuses on advancing cancer treatment through its lead candidate, gedatolisib, and its CELsignia companion diagnostic platform, aiming for a Phase 3 study in HR+/HER2- advanced breast cancer.

MINNEAPOLIS, MN / ACCESSWIRE / May 26, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients with cancer, today announced that Brian Sullivan, Chairman, Chief Executive Officer, and Co-founder of Celcuity, will participate in the following investor conferences:

• One-on-one and small group meetings at the 19th Annual Craig-Hallum Institutional Investor Conference (virtual) on Wednesday, June 1, 2022; and
• A fireside chat at the Jefferies Healthcare Conference in New York at 2:30 p.m. ET on Thursday, June 9, 2022. A live webcast will be available using this weblink: https://wsw.com/webcast/jeff240/celc/1811175. Alternatively, the live webcast will be accessible from the Investors section of the company's website at https://celcuity.com/investors/events-webcasts/ with a replay available shortly after the live event.

About Celcuity
Celcuity is a clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated therapeutic and companion diagnostic strategy. The company's lead therapeutic candidate is gedatolisib, a potent, reversible dual inhibitor that selectively targets all Class I isoforms of PI3K and mTOR. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. The company expects to initiate a Phase 3 study evaluating gedatolisib in patients with HR+/HER2- advanced breast cancer in 2022. Its CELsignia companion diagnostic platform is uniquely able to analyze live patient tumor cells to identify new groups of cancer patients likely to benefit from already approved targeted therapies. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at www.celcuity.com.

CONTACT
Celcuity Inc.
Brian Sullivan, bsullivan@celcuity.com
Vicky Hahne, vhahne@celcuity.com
(763) 392-0123

ICR Westwicke
Robert Uhl, robert.uhl@westwicke.com
(619) 228-5886

SOURCE: Celcuity Inc.

View source version on accesswire.com:
https://www.accesswire.com/702798/Celcuity-to-Participate-in-Upcoming-Craig-Hallum-and-Jefferies-Investor-Conferences

FAQ

What upcoming conferences will Celcuity participate in?

Celcuity will participate in the Craig-Hallum Institutional Investor Conference on June 1, 2022, and the Jefferies Healthcare Conference on June 9, 2022.

Who is the CEO of Celcuity and what event will he attend?

Brian Sullivan, the CEO of Celcuity, will attend the Craig-Hallum Conference and the Jefferies Healthcare Conference.

What is the significance of gedatolisib for Celcuity?

Gedatolisib is Celcuity's lead therapeutic candidate targeting cancer treatment, specifically set to enter a Phase 3 study for HR+/HER2- advanced breast cancer.

Where can I find the live webcast for Celcuity's conference participation?

The live webcast for the Jefferies Healthcare Conference can be found on Celcuity's website or via the provided weblink.

What is the focus of Celcuity as a biotechnology company?

Celcuity focuses on developing integrated therapeutic and companion diagnostic strategies for cancer treatment.